Recent Advances in the Treatment of Melanoma von Curti, Brendan D, Faries, Mark B

Volltext

Immunotherapy in Advanced Renal Cancer — Is Cure Possible? von Curti, Brendan D

Volltext

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma von Sarnaik, Amod A., Hamid, Omid, Khushalani, Nikhil, Lewis, Karl D., Medina, Theresa, Kluger, Harriet M., Thomas, Sajeve S., Domingo-Musibay, Evidio, Pavlick, Anna C., Whitman, Eric D., Martin-Algarra, Salvador, Corrie, Pippa, Curti, Brendan D., Olah, Judit, Lutzky, Jose, Weber, Jeffrey S., Larkin, James M. G., Shi, Wen, Takamura, Toshimi, Jagasia, Madan, Qin, Harry, Wu, Xiao, Chartier, Cecile, Finckenstein, Friedrich Graf, Fardis, Maria, Kirkwood, John M., Chesney, Jason A.

Volltext

OX40 is a potent immune-stimulating target in late-stage cancer patients von Curti, Brendan D, Kovacsovics-Bankowski, Magdalena, Morris, Nicholas, Walker, Edwin, Chisholm, Lana, Floyd, Kevin, Walker, Joshua, Gonzalez, Iliana, Meeuwsen, Tanisha, Fox, Bernard A, Moudgil, Tarsem, Miller, William, Haley, Daniel, Coffey, Todd, Fisher, Brenda, Delanty-Miller, Laurie, Rymarchyk, Nicole, Kelly, Tracy, Crocenzi, Todd, Bernstein, Eric, Sanborn, Rachel, Urba, Walter J, Weinberg, Andrew D

Volltext

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells von Duhen, Rebekka, Ballesteros-Merino, Carmen, Frye, Alexandra K., Tran, Eric, Rajamanickam, Venkatesh, Chang, Shu-Ching, Koguchi, Yoshinobu, Bifulco, Carlo B., Bernard, Brady, Leidner, Rom S., Curti, Brendan D., Fox, Bernard A., Urba, Walter J., Bell, R. Bryan, Weinberg, Andrew D.

Volltext

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors von Bentebibel, Salah-Eddine, Hurwitz, Michael E, Bernatchez, Chantale, Haymaker, Cara, Hudgens, Courtney W, Kluger, Harriet M, Tetzlaff, Michael T, Tagliaferri, Mary A, Zalevsky, Jonathan, Hoch, Ute, Fanton, Christie, Aung, Sandra, Hwu, Patrick, Curti, Brendan D, Tannir, Nizar M, Sznol, Mario, Diab, Adi

Volltext

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma von Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander, Cho, Daniel C., Guan, Shanhong, Puente, Erika, Tuan Nguyen, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.

Volltext

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) von Diab, Adi, Tannir, Nizar M., Bentebibel, Salah-Eddine, Hwu, Patrick, Papadimitrakopoulou, Vassiliki, Haymaker, Cara, Kluger, Harriet M., Gettinger, Scott N., Sznol, Mario, Tykodi, Scott S., Curti, Brendan D., Tagliaferri, Mary A., Zalevsky, Jonathan, Hannah, Alison L., Hoch, Ute, Aung, Sandra, Fanton, Christie, Rizwan, Ahsan, Iacucci, Ernesto, Liao, Yijie, Bernatchez, Chantale, Hurwitz, Michael E., Cho, Daniel C.

Volltext

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 von Atkins, Michael B, Lee, Sandra J, Chmielowski, Bartosz, Tarhini, Ahmad A, Cohen, Gary I, Truong, Thach-Giao, Moon, Helen H, Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J, Curti, Brendan D, Urba, Walter J, Brell, Joanna M, Funchain, Pauline, Kendra, Kari L, Ikeguchi, Alexandra P, Jaslowski, Anthony, Bane, Charles L, Taylor, Mark A, Bajaj, Madhuri, Conry, Robert M, Ellis, Robert J, Logan, Theodore F, Laudi, Noel, Sosman, Jeffrey A, Crockett, David G, Pecora, Andrew L, Okazaki, Ian J, Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X, Streicher, Howard Z, Wolchok, Jedd D, Ribas, Antoni, Kirkwood, John M

Volltext

Rapid Evolution of Combination Therapy in Melanoma von Curti, Brendan D

Volltext

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma von Choueiri, Toni K, Fishman, Mayer N, Escudier, Bernard, McDermott, David F, Drake, Charles G, Kluger, Harriet, Stadler, Walter M, Perez-Gracia, Jose Luis, McNeel, Douglas G, Curti, Brendan, Harrison, Michael R, Plimack, Elizabeth R, Appleman, Leonard, Fong, Lawrence, Albiges, Laurence, Cohen, Lewis, Young, Tina C, Chasalow, Scott D, Ross-Macdonald, Petra, Srivastava, Shivani, Jure-Kunkel, Maria, Kurland, John F, Simon, Jason S, Sznol, Mario

Volltext

Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity von Sckisel, Gail D., Bouchlaka, Myriam N., Monjazeb, Arta M., Crittenden, Marka, Curti, Brendan D., Wilkins, Danice E.C., Alderson, Kory A., Sungur, Can M., Ames, Erik, Mirsoian, Annie, Reddy, Abhinav, Alexander, Warren, Soulika, Athena, Blazar, Bruce R., Longo, Dan L., Wiltrout, Robert H., Murphy, William J.

Volltext

Science gone translational: the OX40 agonist story von Weinberg, Andrew D., Morris, Nicholas P., Kovacsovics-Bankowski, Magdalena, Urba, Walter J., Curti, Brendan D.

Volltext

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results von Diab, Adi, Gogas, Helen, Sandhu, Shahneen, Long, Georgina V, Ascierto, Paolo A, Larkin, James, Sznol, Mario, Franke, Fabio, Ciuleanu, Tudor E, Pereira, Caio, Muñoz Couselo, Eva, Bronzon Damian, Fernanda, Schenker, Michael, Perfetti, Aldo, Lebbe, Celeste, Quéreux, Gaëlle, Meier, Friedegund, Curti, Brendan D, Rojas, Carlos, Arriaga, Yull, Yang, Haisu, Zhou, Ming, Ravimohan, Shruthi, Statkevich, Paul, Tagliaferri, Mary A, Khushalani, Nikhil I

Volltext

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition von Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

Volltext

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma von Feng, Zipei, Puri, Sachin, Moudgil, Tarsem, Wood, William, Hoyt, Clifford C, Wang, Chichung, Urba, Walter J, Curti, Brendan D, Bifulco, Carlo B, Fox, Bernard A

Volltext

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma von Kottschade, Lisa A, Pond, Gregory Russell, Olszanski, Anthony J, Zakharia, Yousef, Domingo-Musibay, Evidio, Hauke, Ralph J, Curti, Brendan D, Schober, Sarah, Milhem, Mohammed M, Block, Matthew Stephen, Hieken, Tina, McWilliams, Robert R

Volltext

Sunitinib in Patients With Metastatic Renal Cell Carcinoma von Motzer, Robert J, Rini, Brian I, Bukowski, Ronald M, Curti, Brendan D, George, Daniel J, Hudes, Gary R, Redman, Bruce G, Margolin, Kim A, Merchan, Jaime R, Wilding, George, Ginsberg, Michelle S, Bacik, Jennifer, Kim, Sindy T, Baum, Charles M, Michaelson, M. Dror

Volltext

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America von Stadler, Walter M., Figlin, Robert A., McDermott, David F., Dutcher, Janice P., Knox, Jennifer J., Miller, Wilson H., Hainsworth, John D., Henderson, Charles A., George, Jeffrey R., Hajdenberg, Julio, Kindwall‐Keller, Tamila L., Ernstoff, Marc S., Drabkin, Harry A., Curti, Brendan D., Chu, Luis, Ryan, Christopher W., Hotte, Sebastien J., Xia, Chenghua, Cupit, Lisa, Bukowski, Ronald M.

Volltext

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies von Fox, Bernard A, Urba, Walter J, Jensen, Shawn M, Page, David B, Curti, Brendan D, Sanborn, Rachel E, Leidner, Rom S

Volltext